glp-1 vs glp-1/gip Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research The pleiotropic effects of GLP-1

It is common in peptide protocols to dose in sub-milligram or low-milligram ranges, meaning one 5 mg vial is often sufficient for multiple doses under research protocols

Semaglutide in patients with obesity-related heart failure and type 2 diabetes

Annu Rev Pharmacol Toxicol

The GLP-1 travel case guide identifies specific product options

Most protocols divide this total amount across 10-20 consecutive days, creating what researchers term an "active cycle." Common Dosage Breakdown: Conservative approach : 5mg total (0.25-0.5mg daily for 10-20 days) Standard protocol : 10mg total (0.5-1mg daily for 10-20 days) Intensive research : Up to 20mg total (1mg daily for 20 days) The epithalon 10mg vial represents the most popular research quantity, providing sufficient material for one complete standard cycle

effects diminish within 2-4 weeks of continuous use Ipamorelin: Maximum Selectivity Ipamorelin was designed specifically for selective GH release: GHS-R1a Selectivity: Activates only GH-releasing pathways at the receptor No Cortisol Effect: Does not stimulate ACTH or cortisol release No Prolactin Effect: Does not affect prolactin levels Minimal Appetite Effect: Unlike other GHRPs, does not significantly increase hunger No Cardiac Activity: Lacks Hexarelin's cardiac receptor effects No Desensitization: Effects maintain with continued use Key Trade-off: Hexarelin offers maximum acute GH release but with hormonal side effects and rapid desensitization